Biotech startups that raised Series A in New York City
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Waypoint Bio | New York | Series A | $20.0M | 2026-05-27 |
| Gilgamesh Pharmaceuticals | New York | Series A | $60.0M | 2026-03-24 |
| Neura Health | New York | Series A | $11.4M | 2025-09-29 |
| Glyphic Biotechnologies | New York | Series A | $38.0M | 2025-09-26 |
| Volastra Therapeutics | New York | Series A | $30.1M | 2025-09-23 |
| Levels | New York | Series A | $10.0M | 2024-08-14 |
| OnCusp Therapeutics | New York | Series A | $100.0M | 2024-01-04 |
| Deep Apple Therapeutics | New York | Series A | $52.0M | 2023-12-14 |
8 rows of the CSV in 5 of its 18 columns.
- The 66 biotech startups in New York City whose last round is Series A have raised $2.3B in total.
- 9 of them closed their most recent round in the last 12 months, $458.0M combined.
- The largest of those rounds is Serapha Bio's $138.0M Series A, dated January 2026.
- The most recent is CAD Therapeutics' $4.0M Series A on 1 October 2026.
- Alumni Ventures is an investor in 3 of them, more than any other fund.
- Health care is the most common other sector, with 59 companies (89%).
- 32% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (58% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
2 of 66| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Waypoint Bio | Waypoint Bio applies spatial biology to improve cell therapy development. | Artificial intelligence | Series A | $20.0M | 2026-05-27 | $34.5M | Village Global, Fifty Years, Hummingbird Ventures +2 | 11 to 50 | 2021 |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. | Biotech | Series A | $60.0M | 2026-03-24 | $142.6M | Y Combinator, Alumni Ventures, Gaingels +2 | 11 to 50 | 2019 |
Table 1. Biotech startups that raised Series A in New York City: the 2 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 66.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. | Biotech | Series A | $60.0M | 2026-03-24 | $142.6M | Y Combinator, Alumni Ventures, Gaingels +2 | 11 to 50 | 2019 |
| 2 | Waypoint Bio | Waypoint Bio applies spatial biology to improve cell therapy development. | Artificial intelligence | Series A | $20.0M | 2026-05-27 | $34.5M | Village Global, Fifty Years, Hummingbird Ventures +2 | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series A in New York City: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Alumni Ventures | Angel group | Manchester, United States | 3 | 5% | 1 | Gilgamesh Pharmaceuticals |
| 2 | National Institutes of Health | Entrepreneurship program | Bethesda, United States | 2 | 3% | ||
| 3 | Catalio Capital Management | Venture capital firm | New York, United States | 2 | 3% | ||
| 4 | Hummingbird Ventures | Venture capital firm | Brussels, Belgium | 1 | 2% | 1 | Waypoint Bio |
| 5 | Village Global | Micro VC fund | Covina, United States | 1 | 2% | 1 | Waypoint Bio |
| 6 | MBX Capital | Venture capital firm | New York, United States | 1 | 2% | 1 | Waypoint Bio |
| 7 | Fifty Years | Micro VC fund | San Francisco, United States | 1 | 2% | 1 | Waypoint Bio |
| 8 | Boom Capital Ventures | Venture capital firm | San Francisco, United States | 1 | 2% | 1 | Waypoint Bio |
| 9 | Prime Movers Lab | Venture capital firm | Jackson, United States | 1 | 2% | 1 | Gilgamesh Pharmaceuticals |
| 10 | Y Combinator | Startup accelerator | Mountain View, United States | 1 | 2% | 1 | Gilgamesh Pharmaceuticals |
| 11 | Gaingels | Syndicate | Burlington, United States | 1 | 2% | 1 | Gilgamesh Pharmaceuticals |
| 12 | Pioneer Fund | Startup accelerator | Toronto, Canada | 1 | 2% | 1 | Gilgamesh Pharmaceuticals |
| 13 | Plug and Play | Startup accelerator | Sunnyvale, United States | 1 | 2% | ||
| 14 | Index Ventures | Venture capital firm | San Francisco, United States | 1 | 2% | ||
| 15 | Norwest | Private equity firm | Menlo Park, United States | 1 | 2% |
Table 3. Biotech startups that raised Series A in New York City: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 59 | 89% | $2.1B |
| Software | 16 | 24% | $392.9M |
| Artificial intelligence | 13 | 20% | $299.0M |
| Hardware | 2 | 3% | $77.7M |
| Cybersecurity | 1 | 2% | $18.0M |
Table 4. Biotech startups that raised Series A in New York City by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 66 | 100% | $22.0M |
Table 5. Biotech startups that raised Series A in New York City by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 1 | 11% | $4.0M |
| September 2026 | 1 | 11% | $55.0M |
| May 2026 | 2 | 22% | $34.0M |
| April 2026 | 1 | 11% | $47.0M |
| March 2026 | 2 | 22% | $110.0M |
| January 2026 | 1 | 11% | $138.0M |
| December 2025 | 1 | 11% | $70.0M |
Table 6. Biotech startups that raised Series A in New York City: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 8 | 12% | $388.0M |
| 2025 | 9 | 14% | $316.9M |
| 2024 | 3 | 5% | $120.0M |
| 2023 | 8 | 12% | $298.6M |
| 2022 | 6 | 9% | $56.7M |
| 2021 | 11 | 17% | $216.5M |
Table 7. Biotech startups that raised Series A in New York City by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 6 | 9% |
| 2020 to 2022 | 15 | 23% |
| 2015 to 2019 | 24 | 36% |
| 2010 to 2014 | 15 | 23% |
| Before 2010 | 6 | 9% |
Table 8. Biotech startups that raised Series A in New York City by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 22 | 34% |
| 11 to 50 | 37 | 58% |
| 51 to 100 | 2 | 3% |
| 101 to 250 | 2 | 3% |
| 5,001 to 10,000 | 1 | 2% |
Table 9. Biotech startups that raised Series A in New York City by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in New York City. On 16 November 2026 that is 66 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 2 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 66 rows: 14 have no round amount, 0 no city and 12 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in New York City whose last round is Series A are on the list?
- 66, in the file dated 16 November 2026. 9 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 66 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.